Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB301 in mild to moderate Alzheimer's disease
NCT03865017Phase 2Unknown
- Sponsor
- VTR Biotech
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgrastim in Alzheimer's disease (AD) (2 arms), sponsored by VTR Biotech. Primary endpoints: Number of subjects With Clinically Significant Abnormalities in 12-lead Electrocardiogram at 12 weeks, Number of subjects with abnormal clinical chemistry, Hematology, Coagulation, Urinalysis parameters at 12 weeks and 3 more. Status: unknown.
02
Drugs
filgrastim
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03865017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865017.